home / stock / tlt:cc / tlt:cc news

TLT:CC News and Press, Theralase Technologies Inc. From 10/23/23

Stock Information
Company Name: Theralase Technologies Inc.
Stock Symbol: TLT:CC
Market: TSXVC
Website: theralase.com
Menu
TLT:CC TLT:CC Quote TLT:CC Short TLT:CC News TLT:CC Articles TLT:CC Message Board
Get TLT:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
TLT:CC - Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study

Post Study II Monitoring of Response, Optional Maintenance Study II Treatments and Central Pathology Laboratory Review Optimized TORONTO, ON / ACCESSWIRE / October 23, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical ...
TLT:CC - Theralase(R) Provides Update on Bladder Cancer Clinical Study

Theralase®'s Latest Clinical Data Demonstrates 65% of Patients Treated with Theralase®'s Anti-Cancer Therapy Achieved a Complete Response TORONTO, ON / ACCESSWIRE / October 16, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLT...

TLT:CC - Theralase(R) Files US Patent for Enhanced Immunotherapy

Theralase®'s Latest Preclinical Data Supports Combining Immunotherapy Drugs with Theralase® PDCs for Increased Cancer Destruction TORONTO, ON / ACCESSWIRE / October 5, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a...

TLT:CC - Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)

TORONTO, ON / ACCESSWIRE / September 29, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activated Photo Dynamic Com...
TLT:CC - Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer

TORONTO, ON / ACCESSWIRE / September 27, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activatedPhoto Dynamic Comp...

TLT:CC - Theralase(R) Grants Stock Options

TORONTO, ON / ACCESSWIRE / September 21, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDCs "), their ...

TLT:CC - Theralase(R) Closes Private Placement Equity Financing

TORONTO, ON / ACCESSWIRE / September 7, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), is a clinical stage pharmaceutical company focused on the research, development and commercialization of light activated Photo Dynamic Compou...
TLT:CC - Theralase Release's 2Q2023 Interim Financial Statements

TORONTO, ON / ACCESSWIRE / August 29, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDCs "), their as...

TLT:CC - Theralase(R) Closes Non-Brokered Private Placement Equity Financing

TORONTO, ON / ACCESSWIRE / June 30, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (" PDCs ") and their as...

TLT:CC - Theralase Technologies shares positive interim results from Phase II Bladder Cancer study

--News Direct-- Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share interim data from a Phase II clinical study designed to treat patients diagnosed with Bacillus Calmette-Guérin Unresponsive, Non-Muscle Invasive Bladder Cancer and Carcinoma I...
Previous 10 Next 10